Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Gilead boosts antiviral drug investment
by Ryan Cross
July 25, 2019
| A version of this story appeared in
Volume 97, Issue 30
Gilead Sciences has licensed three small-molecule antiviral programs from Novartis. Gilead will pay an undisclosed sum and up to $291 million in future milestones for Novartis’s herpes virus, influenza, and rhinovirus programs. Separately, Gilead will pay Durect $25 million to license a long-lasting injectable antiviral for HIV. Durect could earn $145 million more in milestone payments, and Gilead has the option to license additional Durect antiviral programs for HIV and hepatitis B.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter